Principal Financial Group
ENZN

Principal Financial Group’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Principal Financial Group’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-16,038
Closed -$17K – 2370
2014
Q1 		$17K Sell
16,038
-328
-2% -$339 ﹤0.01% 2256
2013
Q4 		$19K Sell
16,366
-303
-2% -$467 ﹤0.01% 2274
2013
Q3 		$28K Sell
16,669
-1,067
-6% -$1.97K ﹤0.01% 2258
2013
Q2 		$35K Buy
+17,736
New +$51.9K ﹤0.01% 2247

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Financial Group's ENZN Position: Q2 2014 in Review

Principal Financial Group sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2014, closing a stake of 16,038 shares — an estimated $17K sold.

Principal Financial Group first reported a position in ENZN in Q2 2013 and held it in 4 quarters. The position peaked at $35K in Q2 2013. 67 funds tracked by Wall St. Rank hold ENZN as of Q2 2014.

  • Principal Financial Group reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2014 after selling out during the quarter.
  • Principal Financial Group sold 16,038 ENZON PHARMACEUTICALS INC shares in Q2 2014, an estimated $17K.
  • Principal Financial Group first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 4 quarters.
  • Principal Financial Group's ENZON PHARMACEUTICALS INC position peaked at $35K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2014.

Based on Principal Financial Group's 13F filing for Q2 2014, filed 12 Aug 2014.